Niacin is a pleotropic molecule, reducing levels of all atherogenic particles containing apoB, including LDL-C, triglycerides, and Lp(a). Although niacin is the only known substance to significantly increase HDL cholesterol, a large body of clinical evidence has found it significantly reduces both cardiovascular events and major coronary heart disease, potentially through unrelated mechanisms. It improves endothelial function, and reduces carotid intima-media thickness and C-reactive protein among participants with the metabolic syndrome. The intermediate release form is the treatment of choice, as it is associated both with lower hepatic toxicity as well as reduced flushing.
Benefits: Provides niacin (nicotinic acid) as intermediate release form; extensively documented improvement in dyslipidemia and inflammation. High potency dosing, with 500 mg nicotinic acid, 75 mg Sytrinol, and 62.5 mg Hibiscus sabdariffa per tablet, all clinically relevant dosages. Intermediate release form of niacin avoids both the hepatotoxicity and cutaneous flushing common to other forms. Well-suited for patients with mixed dyslipidemias, considering multiple lipidmodifying and anti-inflammatory effects of diverse anti-atherogenic ingredients.
Serving Size: 1 Tablet.
Amount Per Serving: Niacin ... 500mg (nicotinic acid) Calcium ... 133mg (dicalcium phosphate) Sytrinol ... 75mg Orange Extract ... 67.5mg (Citrus aurantium or Citrus nobilis)(peel)(24.3 mg polymethoxylated flavones) Palm Extract ... 62.5mg (Elaeis guineensis)(seed oil)(1.125 mg tocotrienols) 7.5 mg Hibiscus sabdariffa 4:1 Extract (flower) (Standardized to contain 6% anthocyanins).
This product has not been evaluated by the FDA. It is not intended to diagnose, treat, cure or prevent any disease.
No comments:
Post a Comment